|

Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma

RECRUITINGSponsored by Grigore T. Popa University of Medicine and Pharmacy
Actively Recruiting
SponsorGrigore T. Popa University of Medicine and Pharmacy
Started2026-10-08
Est. completion2027-10
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older. The study will investigate whether these biomarkers can help distinguish pancreatic cancer from chronic pancreatitis and mucinous pancreatic lesions, including intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs). The main questions it aims to answer are: Can blood-based protein biomarkers accurately identify patients with PDAC and distinguish them from patients with chronic pancreatitis or mucinous pancreatic lesions? Does combining protein biomarkers with CA 19-9 improve diagnostic accuracy compared with using individual biomarkers alone? Are protein biomarker levels associated with tumor stage, tumor size, or the presence of metastases in patients with PDAC? Researchers will compare blood levels of protein biomarkers across four groups of patients: those with PDAC, chronic pancreatitis, IPMNs, and MCNs. The biomarkers will include GDF-15, ICAM-1, osteopontin, CXCL10, HGF, Nectin-4, periostin, and VEGF-A. Participants will: Provide informed consent before enrollment. Provide an additional blood sample for protein biomarker measurement, collected alongside routine blood tests and before any oncological or interventional treatment. Have relevant clinical information, medical history, laboratory results, and imaging findings collected for analysis.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion criteria:

* Adults aged 18 years or older
* Diagnosis of pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis, intraductal papillary mucinous neoplasm (IPMN), or mucinous cystic neoplasm (MCN)
* Histopathological confirmation mandatory for PDAC and optional for benign pancreatic conditions
* Diagnosis of benign pancreatic conditions confirmed by imaging criteria and/or a minimum clinical follow-up of 12 months
* Written informed consent

Exclusion criteria:

* Less than 3 months since resolution of the most recent episode of acute pancreatitis
* Other active malignancies
* Severe systemic inflammatory diseases
* Oncological treatment initiated before blood sample collection, including chemotherapy or surgical resection
* Refusal to participate

Conditions5

CancerChronic PancreatitisIntraductal Papillary Mucinous NeoplasmMucinous Cystic NeoplasmPancreatic Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.